Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.

Ding H, Carlton MM, Povoski SP, Milum K, Kumar K, Kothandaraman S, Hinkle GH, Colcher D, Brody R, Davis PD, Pokora A, Phelps M, Martin EW Jr, Tweedle MF.

Bioconjug Chem. 2013 Nov 20;24(11):1945-54. doi: 10.1021/bc400375f. Epub 2013 Oct 31.

2.

Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen.

Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Rahimi Jamnani F, Aghaee Bakhtiari SH.

Mol Biotechnol. 2013 Jun;54(2):590-601. doi: 10.1007/s12033-012-9601-0.

PMID:
23015323
3.

Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents.

Chen L, Wang Y, Cheng D, Dou S, Liu X, Liu G, Hnatowich DJ, Rusckowski M.

Nucl Med Commun. 2011 Oct;32(10):920-4. doi: 10.1097/MNM.0b013e328348fc64.

4.

Identification of a high affinity TAG-72 binding peptide by phage display selection.

Xiao N, Cheng D, Wang Y, Chen L, Liu X, Dou S, Liu G, Liang M, Hnatowich DJ, Rusckowski M.

Cancer Biol Ther. 2011 Jan 1;11(1):22-31. Epub 2011 Jan 1.

5.

Tumor targeting of humanized fragment antibody secreted from transgenic rice cell suspension culture.

Hong SY, Lee TS, Kim J, Jung JH, Choi CW, Kim TG, Kwon TH, Jang YS, Yang MS.

Plant Mol Biol. 2008 Nov;68(4-5):413-22. doi: 10.1007/s11103-008-9379-4. Epub 2008 Aug 1.

PMID:
18670890
6.
7.

Evidence of specificity of radiolabeled phage display peptides for the TAG-72 antigen.

Rusckowski M, Gupta S, Liu G, Dou S, Hnatowich DJ.

Cancer Biother Radiopharm. 2007 Aug;22(4):564-72.

PMID:
17803452
8.
9.

Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, Liu A, Ueda R, Hodges D, Escandon E, Chen T, Kanavarioti T, Babé L, Senter PD, Fox JA, Schellenberger V.

Bioconjug Chem. 2006 Mar-Apr;17(2):410-8.

PMID:
16536473
10.

Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody.

Yoon SO, Lee TS, Kim SJ, Jang MH, Kang YJ, Park JH, Kim KS, Lee HS, Ryu CJ, Gonzales NR, Kashmiri SV, Lim SM, Choi CW, Hong HJ.

J Biol Chem. 2006 Mar 17;281(11):6985-92. Epub 2006 Jan 9.

11.

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.

Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ.

Cancer Biother Radiopharm. 2005 Oct;20(5):502-13. Erratum in: Cancer Biother Radiopharm. 2005 Dec;20(6):671.

PMID:
16248766
12.

Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.

Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.

J Immunol Methods. 2005 Nov 30;306(1-2):93-103. Epub 2005 Oct 3.

PMID:
16236307
13.

Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies.

Glaser SM, Hughes IE, Hopp JR, Hathaway K, Perret D, Reff ME.

J Biol Chem. 2005 Dec 16;280(50):41494-503. Epub 2005 Oct 12.

14.

Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49.

Wittel UA, Jain M, Goel A, Baranowska-Kortylewicz J, Kurizaki T, Chauhan SC, Agrawal DK, Colcher D, Batra SK.

Biochem Biophys Res Commun. 2005 Apr 1;329(1):168-76.

PMID:
15721289
15.

Design and construction of a phosphorylatable chimeric monoclonal antibody with a highly stable phosphate.

Wu W, Kerrigan JE, Yadav P, Schwartz B, Izotova L, Lavoie TB, Pestka S.

Oncol Res. 2004;14(11-12):541-58.

PMID:
15666996
16.

Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs.

Pavlinkova G, Colcher D, Booth BJ, Goel A, Wittel UA, Batra SK.

Int J Cancer. 2001 Dec 1;94(5):717-26.

17.

Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.

Pavlinkova G, Booth BJ, Batra SK, Colcher D.

Clin Cancer Res. 1999 Sep;5(9):2613-9.

18.
19.

Construction of phosphorylatable chimeric monoclonal antibody CC49 with a casein kinase I recognition site.

Lin L, Gillies SD, Schlom J, Pestka S.

Protein Expr Purif. 1999 Feb;15(1):83-91.

PMID:
10024474
20.

Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor.

McGuinness RP, Ge Y, Patel SD, Kashmiri SV, Lee HS, Hand PH, Schlom J, Finer MH, McArthur JG.

Hum Gene Ther. 1999 Jan 20;10(2):165-73.

PMID:
10022542
Items per page

Supplemental Content

Loading ...
Write to the Help Desk